PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Dexamethasone - Uveitis

PAD Profile : Dexamethasone - Uveitis Important

Keywords :
non-infectious uveitis
Brand Names Include :
Ozurdex
Important Information :
Ophthalmology specialists only

Traffic Light Status

Status 1 of 1.

Status :
Red
Formulations :
  • Intravitreal implant
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
04 October 2017
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The PCN recommends Intravitreal dexamethasone implant (Ozurdex) for the treatment of non-infectious Uveitis in line with NICE TA460 Ozurdex is a payment by results excluded drug and will be considered RED on the traffic light system with treatment being provided by ophthalmology specialist teams in secondary care. Specialists will be expected to notify commissioners through blueteq by completing tick box proformas for initiation and repeat implants.

Associated BNF Codes

11. Eye
11.04.01. Corticosteroids
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More